These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The use of clofibrate in patients with renal insufficiency. Viikari J; Anttila M; Kasanen A Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):77-80. PubMed ID: 6840929 [TBL] [Abstract][Full Text] [Related]
6. On the metabolism of clofibride, a hypolipaemic drug. Loiseau GP; Millischer RJ; Lohier PY; Mardiguian JS; Gilede AM; Ginocchio AV J Pharm Pharmacol; 1980 Jul; 32(7):483-8. PubMed ID: 6105184 [TBL] [Abstract][Full Text] [Related]
7. Clofibrate kinetics after single and multiple doses. Gugler R; Hartlapp J Clin Pharmacol Ther; 1978 Oct; 24(4):432-8. PubMed ID: 688733 [TBL] [Abstract][Full Text] [Related]
9. Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man. Houin G; Shastri RA; Barre J; Pinchon B; Tillement JP Br J Clin Pharmacol; 1984 Mar; 17(3):341-5. PubMed ID: 6712867 [TBL] [Abstract][Full Text] [Related]
10. [A quantitative gaschromatographic method for the determination of p-chlorophenoxyisobutyric acid (clofibrinic acid) in human plasma (author's transl)]. Häselbarth V Arzneimittelforschung; 1976; 26(11):2076-80. PubMed ID: 1037251 [TBL] [Abstract][Full Text] [Related]
11. [Studies on the mechanism of lowering of the cholesterol level by ethyl-alpha-p-chlorophenoxy-isobutyrate (clofibrate) (author's transl)]. Nakamura H Hokkaido Igaku Zasshi; 1976 Jul; 51(4):289-97. PubMed ID: 1033897 [TBL] [Abstract][Full Text] [Related]
13. Cholesterol absorption in man: effect of administration of clofibrate and/or cholestyramine. McNamara DJ; Davidson NO; Samuel P; Ahrens EH J Lipid Res; 1980 Nov; 21(8):1058-64. PubMed ID: 7462801 [TBL] [Abstract][Full Text] [Related]
14. Restraint of cholesterol accumulation in tissue pools associated with drastic short-term lowering of serum cholesterol levels by clofibrate or cholestyramine in hypercholesterolemic swine. Kim DN; Lee KT; Reiner JM; Thomas WA J Lipid Res; 1974 Jul; 15(4):326-31. PubMed ID: 4854142 [TBL] [Abstract][Full Text] [Related]
15. Disposition of clofibrate in the rat. Acute and chronic administration. Baldwin JR; Witiak DT; Feller DR Biochem Pharmacol; 1980 Dec; 29(23):3143-54. PubMed ID: 7447955 [No Abstract] [Full Text] [Related]
16. Separation of two conjugates of clofibric acid (CPIB) found in the urine of subjects taking clofibrate. Faed EM; McQueen EG Clin Exp Pharmacol Physiol; 1978; 5(2):195-8. PubMed ID: 648038 [TBL] [Abstract][Full Text] [Related]
17. Measurement of clofibric acid (CPIB) metabolites in plasma of patients on clofibrate therapy. Faed EM; McQueen EG Clin Exp Pharmacol Physiol; 1979; 6(3):267-73. PubMed ID: 466868 [TBL] [Abstract][Full Text] [Related]
18. Effects of clofibrate, cholestyramine, zanchol, probucol, and AOMA feeding on hepatic and intestinal cholesterol metabolism and on biliary lipid secretion in the rat. Turley SD; Dietschy JM J Cardiovasc Pharmacol; 1980; 2(3):281-97. PubMed ID: 6156326 [TBL] [Abstract][Full Text] [Related]
19. Dose-dependent pharmacokinetics of clofibric acid in the non-human primate. Walmsley LM Arch Toxicol Suppl; 1984; 7():272-7. PubMed ID: 6595991 [TBL] [Abstract][Full Text] [Related]
20. Biliary lipid composition during treatment with different hypolipidaemic drugs. Angelin B; Einarsson K; Leijd B Eur J Clin Invest; 1979 Jun; 9(3):185-90. PubMed ID: 113218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]